Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14883192 | 0.77 | HCRTR1 (0.36) | HCRTR2HCRTR1 | |
| SCHEMBL19315148 | 0.77 | HCRTR2 (0.39) | HCRTR2HCRTR1HTR2AHTR2CHTR2B | |
| SCHEMBL18415719 | 0.73 | HCRTR2 (0.35) | HCRTR2HCRTR1ALOX5HTR2AHTR2C | |
| SCHEMBL14885654 | 0.72 | IDH1 (0.33) | HCRTR2HCRTR1HTR2AHTR2CHTR2B | |
| SCHEMBL17071979 | 0.71 | HCRTR2 (0.47) | HCRTR2HCRTR1POLBTDP1 | |
| SCHEMBL1672510 | 0.71 | TDP1 (0.57) | HCRTR2HCRTR1POLBTDP1 | |
| SCHEMBL17586768 | 0.71 | TXNRD1 (0.36) | TXNRD1PDE10APOLBTDP1 | |
| SCHEMBL12049970 | 0.71 | POLB (0.47) | TXNRD1PDE10APOLBTDP1 | |
| SCHEMBL2609304 | 0.71 | NNMT (0.46) | TXNRD1PDE10APOLBTDP1 | |
| SCHEMBL20375150 | 0.71 | TXNRD1 (0.36) | TXNRD1PDE10APOLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156819-B2 | 2-pyridyloxy-4-nitrile orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102619-A1 | 2-PYRIDYLOXY-4-NITRILE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885HCRTR1 2/4885ALOX5 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.